Article
Radiology, Nuclear Medicine & Medical Imaging
Shuxian An, Di Zhang, You Zhang, Cheng Wang, Liang Shi, Weijun Wei, Gang Huang, Jianjun Liu
Summary: In this study, GPC3-targeted immunoPET imaging strategies were successfully developed and showed superior diagnostic accuracy in preclinical HCC models. A fusion protein ABDG2 with improved targeting and pharmacokinetic properties was also synthesized, serving as a promising candidate for developing radioimmunotherapy agents.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Oncology
Sinan Wang, Jun Li, Jun Hua, Yang Su, Denis R. Beckford-Vera, Walter Zhao, Mayuri Jayaraman, Tony L. Huynh, Ning Zhao, Yung-hua Wang, Yangjie Huang, Fujun Qin, Sui Shen, Daniel Gioeli, Robert Dreicer, Renuka Sriram, Emily A. Egusa, Jonathan Chou, Felix Y. Feng, Rahul Aggarwal, Michael J. Evans, Youngho Seo, Bin Liu, Robert R. Flavell, Jiang He
Summary: The novel CD46-targeted PET radiopharmaceutical [Zr-89]DFO-YS5 shows specific binding and uptake in human prostate cancer models, including PSMA-negative and AR-negative tumors, demonstrating potential for clinical translation as an imaging agent and biomarker in prostate cancer.
CLINICAL CANCER RESEARCH
(2021)
Review
Medicine, General & Internal
Reyhaneh Manafi-Farid, Bahar Ataeinia, Shaghayegh Ranjbar, Zahra Jamshidi Araghi, Mohammad Mobin Moradi, Christian Pirich, Mohsen Beheshti
Summary: Immuno-positron emission tomography (immunoPET) is a molecular imaging technique that combines the high sensitivity of PET with the targeted ability of monoclonal antibodies. While various radioimmunotracers have been developed, only a few have been translated into clinical practice due to issues such as slow kinetics, high physiological uptake, and heterogeneous activity. Efforts are being made to overcome these limitations and develop new tracers.
FRONTIERS IN MEDICINE
(2022)
Article
Medicine, Research & Experimental
Julia Schmitt, Johannes Schwenck, Andreas Maurer, Mirko Przybille, Dominik Sonanini, Gerald Reischl, Joeri E. Wehrmueller, Leticia Quintanilla-Martinez, Stephen D. Gillies, Marcel A. Krueger, Juergen F. Schaefer, Christian la Fougere, Rupert Handgretinger, Bernd J. Pichler
Summary: This study investigated the influence of radiolabeling on the binding characteristics of ch14.18 antibodies targeting GD2 in neuroblastoma immunotherapy. The results showed that Cu-64-labeled ch14.18/CHO was suitable for specific identification of neuroblastoma in PET, with the potential for clinical translation and image-guided therapy.
Article
Oncology
Federico Simonetta, Israt S. Alam, Juliane K. Lohmeyer, Bita Sahaf, Zinaida Good, Weiyu Chen, Zunyu Xiao, Toshihito Hirai, Lukas Scheller, Pujan Engels, Ophir Vermesh, Elise Robinson, Tom Haywood, Ataya Sathirachinda, Jeanette Baker, Meena B. Malipatlolla, Liora M. Schultz, Jay Y. Spiegel, Jason T. Lee, David B. Miklos, Crystal L. Mackall, Sanjiv S. Gambhir, Robert S. Negrin
Summary: The monitoring of CAR T-cell therapy primarily relies on quantification in peripheral blood, which may not reflect their distribution and activation status in tissues. This study evaluated the potential of antibody-based PET imaging for noninvasively visualizing CAR T cells.
CLINICAL CANCER RESEARCH
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Megan Minnix, Vikram Adhikarla, Enrico Caserta, Erasmus Poku, Russell Rockne, John E. Shively, Flavia Pichiorri
Summary: Beta emitter therapy can extend survival but does not delay tumor growth, while alpha emitter therapy at different doses significantly prolongs survival and has a significant delay in tumor growth.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Cheng Wang, Yumei Chen, Yun Nan Hou, Qiufang Liu, Di Zhang, Haitao Zhao, You Zhang, Shuxian An, Lianghua Li, Jian Hou, Gang Huang, Jianjun Liu, Yong Juan Zhao, Weijun Wei
Summary: This study aimed to develop a CD38-targeted immunoPET imaging approach for diagnosing multiple myeloma (MM). By labeling a CD38-specific single domain antibody with Ga-68, a probe was developed with high diagnostic accuracy in preclinical MM models. The immunoPET imaging with this probe showed superior performance in visualizing CD38 and diagnosing MM lesions.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Medicine, Research & Experimental
Chenyi Liang, Wei Huang, You Zhang, Di Zhang, Shuxian An, Qianyun Wu, Haitao Zhao, Cheng Wang, Gang Huang, Weijun Wei, Jianjun Liu
Summary: This study aimed to evaluate the diagnostic value of novel immunoPET tracers targeting CD47 in preclinical pancreatic cancer models. The results showed that these tracers can effectively annotate the expression of CD47 and diagnose pancreatic cancer in a target-specific manner. The findings have implications for patient selection for CD47-targeted therapies and assessment of treatment response.
MOLECULAR PHARMACEUTICS
(2023)
Review
Pharmacology & Pharmacy
Yiting Dun, Gang Huang, Jianjun Liu, Weijun Wei
Summary: Immuno-positron emission tomography (immunoPET) imaging is a revolutionary tumor detection technique that combines the specificity of tumor-targeting vectors and the sensitivity of PET imaging to comprehensively reveal tumor antigen expression. This review summarizes the use of immunoPET in imaging hematological malignancies and discusses the current conjugation strategies and the potential of modular chemistry for developing novel immunoPET probes. Additionally, the use of immunoPET imaging in guiding antibody drug development is also discussed.
DRUG DISCOVERY TODAY
(2022)
Review
Medicine, Research & Experimental
Qing Wang, Xindi Zhang, Weijun Wei, Min Cao
Summary: Despite advances in cancer treatment, lung cancer remains a leading cause of cancer mortality. Immunotherapies using immune checkpoint inhibitors have shown promise in treating lung cancer. ImmunoPET, utilizing radiolabeled monoclonal antibodies or antibody derivatives as tracers, offers advantages over traditional PET imaging in lung cancer detection, diagnosis, staging, risk stratification, treatment guidance, and recurrence monitoring. ImmunoPET holds potential for patient stratification and response evaluation in immunotherapy. This review summarizes the value of immunoPET in imaging lung cancers and optimizing immunotherapy in NSCLC.
MOLECULAR PHARMACEUTICS
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Wei Huang, Chenyi Liang, You Zhang, Di Zhang, Shuxian An, Qianyun Wu, Jiajin Li, Haitao Zhao, Cheng Wang, Jiujie Cui, Zhouzhou Bao, Gang Huang, Weijun Wei, Jianjun Liu
Summary: This study developed nanobody tracers targeting Trop2 for the diagnosis of preclinical pancreatic and gastric cancer models. The results showed high expression of Trop2 in pancreatic cancer cells and tissues, and the probes could accurately delineate tumors in both cell-derived and patient-derived models, outperforming other probes.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Oncology
Justin B. Hackett, Nicholas Ramos, Stephen Barr, Madeline Bross, Nerissa T. Viola, Heather M. Gibson
Summary: This study investigated the use of [89Zr]Zr-DFO-anti-IFN gamma PET tracer for monitoring response to immune checkpoint inhibitors (ICIs). The tracer showed significantly higher intratumoral localization in ICI-treated mice compared to untreated controls, suggesting its potential for detecting immune activity in situ.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biochemical Research Methods
Thomas T. C. Yue, Ying Ge, Francesco A. Aprile, Michelle T. Ma, Truc T. Pham, Nicholas J. Long
Summary: Bioconjugates of antibodies and their derivatives labeled with beta(+)-emitting radionuclides can be used for diagnostic PET imaging. Site-specific attachment of radioactive cargo to antibody delivery vectors provides well-defined immunoconjugates. This study demonstrates the successful application of the oxaziridine chemistry for site-specific radiolabeling of trastuzumab-derived Fab immunoconjugates with Ga-68. The resulting radiotracers show higher affinity for HER2 receptors and better tumor delineation in PET imaging compared to non-modified conjugates.
BIOCONJUGATE CHEMISTRY
(2023)
Article
Chemistry, Medicinal
Ji-Hun Park, Xuran Zhang, Hyunsoo Ha, Jung Kim, Joon Choi, Kyung-Han Lee, Youngjoo Byun, Yearn Choe
Summary: This study aimed to develop a radioligand for positron emission tomography (PET) imaging of Hepsin, a potential biomarker for prostate cancer. Through the synthesis and evaluation of various ligands, a promising PET radioligand with high binding affinity and selectivity for Hepsin was selected. The radioligand exhibited high binding to prostate cancer cells and showed promising imaging results in a prostate tumor mouse model.
Article
Medicine, Research & Experimental
Cuicui Li, Qi Yang, Zhao Chen, Yongkang Qiu, Yujing Du, Rongfu Wang, Qihua He, Jigang Yang, Hongying Zhen, Lei Kang
Summary: This study evaluated the expression of ABCG2 in lung cancer multidrug resistance models using fluorescent and immunoPET imaging, which may be used for the diagnosis and treatment selection for lung cancer multidrug resistance patients in future applications.
MOLECULAR PHARMACEUTICS
(2022)